Full Press Release Details
Life Sciences plc Invites You to Join Us at the Q3 Virtual Investor Summit
YORK & LONDON, August 16, 2021 - Tiziana Life Sciences plc (NASDAQ: TLSA, LSE: TILS) ("Tiziana" or the "Company"),
a biotechnology company focused on innovative therapeutics for oncology, neurology, inflammation and infectious diseases, announces today
that Dr. Kunwar Shailubhai, CEO & CSO will be attending the Q3 Virtual Investor Summit.
| Event | Q3 Investor Summit |
| Date | August 17-18th, 2021 |
| Presentation | August 18th at 3.30pm ET |
| Location | https://zoom.us/webinar/register/WN_Az9VTw1QRr6aESxsPWSloQ |
Tiziana Life Sciences plc
Tiziana Life Sciences plc (NASDAQ: TLSA) (LSE: TILS)
is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and
immunology. In addition to Milciclib (a CDK inhibitor being developed in oncology), the Company is also developing Foralumab in COVID-19,
multiple sclerosis, and Crohn's Disease. Foralumab is the only second generation fully human anti-CD3 monoclonal antibody in clinical
development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such
as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis
and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin
6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammatory pulmonary diseases.
further information:
Investor Summit is an exclusive, independent conference dedicated to connecting smallcap and microcap companies with qualified investors.
The Q3 Investor Summit will take place virtually, featuring 80+ companies and over 800 investors, consisting of institutional investors,
family offices, and private wealth.
request complimentary investor registration: please click here: Complimentary Investor Registration
Murray at sasha@investorsummitgroup.com